Clinical trial · no report yet · Phase 2
MRD GATE RCC
Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
- NCT06005818 ↗
- Recruiting
- University of Alabama at Birmingham
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Renal Cell Carcinoma
- Interventions
- Pembrolizumab injection
- Arms
- Arm 1: MRD negative patients · No intervention
- Arm 2 MRD positive patients · Active comparator
- Enrollment
- 100 (estimated)
- Primary outcomes
- Disease Free Survival (DFS) by Investigator's assessment as defined by RECIST 1.1
- Sponsor
- University of Alabama at Birmingham
- Start
- Jan 1, 2024
- Primary completion
- Jul 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06005818 · updated Oct 21, 2025